Outcome reliability in non-Ambulatory Boys/Men with duchenne muscular dystrophy

MDA DMD Clinical Research Network

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Introduction: Therapeutic trials in Duchenne muscular dystrophy (DMD) often exclude non-ambulatory individuals. Here we establish optimal and reliable assessments in a multicenter trial. Methods: Non-ambulatory boys/men with DMD (N=91; 16.7±4.5 years of age) were assessed by trained clinical evaluators. Feasibility (percentage completing task) and reliability [intraclass correlation coefficients (ICCs) between morning and afternoon tests] were measured. Results: Forced vital capacity (FVC), assessed in all subjects, showed a mean of 47.8±22% predicted (ICC 0.98). Brooke Upper Extremity Functional Rating (Brooke) and Egen Klassifikation (EK) scales in 100% of subjects showed ICCs ranging from 0.93 to 0.99. Manual muscle testing, range of motion, 9-hole peg test, and Jebsen-Taylor Hand Function Test (JHFT) demonstrated varied feasibility (99% to 70%), with ICCs ranging from 0.99 to 0.64. We found beneficial effects of different forms of corticosteroids for the Brooke scale, percent predicted FVC, and hand and finger strength. Conclusions: Reliable assessment of non-ambulatory boys/men with DMD is possible. Clinical trials will have to consider corticosteroid use.

Original languageEnglish (US)
Pages (from-to)522-532
Number of pages11
JournalMuscle and Nerve
Volume51
Issue number4
DOIs
StatePublished - Apr 1 2015

Fingerprint

Duchenne Muscular Dystrophy
Vital Capacity
Adrenal Cortex Hormones
Hand Strength
Articular Range of Motion
Upper Extremity
Fingers
Multicenter Studies
Hand
Clinical Trials
Muscles
Therapeutics

Keywords

  • Corticosteroids
  • Duchenne muscular dystrophy
  • Non-ambulatory
  • Pulmonary function
  • Quality of life
  • Strength

ASJC Scopus subject areas

  • Clinical Neurology
  • Cellular and Molecular Neuroscience
  • Physiology (medical)
  • Physiology

Cite this

Outcome reliability in non-Ambulatory Boys/Men with duchenne muscular dystrophy. / MDA DMD Clinical Research Network.

In: Muscle and Nerve, Vol. 51, No. 4, 01.04.2015, p. 522-532.

Research output: Contribution to journalArticle

MDA DMD Clinical Research Network. / Outcome reliability in non-Ambulatory Boys/Men with duchenne muscular dystrophy. In: Muscle and Nerve. 2015 ; Vol. 51, No. 4. pp. 522-532.
@article{8cc2fbd930d545fc89a2b90ac8fb78c7,
title = "Outcome reliability in non-Ambulatory Boys/Men with duchenne muscular dystrophy",
abstract = "Introduction: Therapeutic trials in Duchenne muscular dystrophy (DMD) often exclude non-ambulatory individuals. Here we establish optimal and reliable assessments in a multicenter trial. Methods: Non-ambulatory boys/men with DMD (N=91; 16.7±4.5 years of age) were assessed by trained clinical evaluators. Feasibility (percentage completing task) and reliability [intraclass correlation coefficients (ICCs) between morning and afternoon tests] were measured. Results: Forced vital capacity (FVC), assessed in all subjects, showed a mean of 47.8±22{\%} predicted (ICC 0.98). Brooke Upper Extremity Functional Rating (Brooke) and Egen Klassifikation (EK) scales in 100{\%} of subjects showed ICCs ranging from 0.93 to 0.99. Manual muscle testing, range of motion, 9-hole peg test, and Jebsen-Taylor Hand Function Test (JHFT) demonstrated varied feasibility (99{\%} to 70{\%}), with ICCs ranging from 0.99 to 0.64. We found beneficial effects of different forms of corticosteroids for the Brooke scale, percent predicted FVC, and hand and finger strength. Conclusions: Reliable assessment of non-ambulatory boys/men with DMD is possible. Clinical trials will have to consider corticosteroid use.",
keywords = "Corticosteroids, Duchenne muscular dystrophy, Non-ambulatory, Pulmonary function, Quality of life, Strength",
author = "{MDA DMD Clinical Research Network} and Connolly, {Anne M.} and Malkus, {Elizabeth C.} and Mendell, {Jerry R.} and Flanigan, {Kevin M.} and Miller, {J. Philip} and Schierbecker, {Jeanine R.} and Siener, {Catherine A.} and Golumbek, {Paul T.} and Zaidman, {Craig M.} and McDonald, {Craig M} and Linda Johnson and Alina Nicorici and Karachunski, {Peter I.} and Day, {John W.} and Kelecic, {Jason M.} and Lowes, {Linda P.} and Alfano, {Lindsay N.} and Darras, {Basil T.} and Kang, {Peter B.} and Janet Quigley and Pasternak, {Amy E.} and Florence, {Julaine M.} and Pallavi Anand and Wulf, {Charlie O.} and Erica Goude and Dalton, {Joline C.} and Laurence Viollet-Callendret and Buser, {Karen K.} and Elizabeth Shriber and Rebecca Parad",
year = "2015",
month = "4",
day = "1",
doi = "10.1002/mus.24346",
language = "English (US)",
volume = "51",
pages = "522--532",
journal = "Muscle and Nerve",
issn = "0148-639X",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - Outcome reliability in non-Ambulatory Boys/Men with duchenne muscular dystrophy

AU - MDA DMD Clinical Research Network

AU - Connolly, Anne M.

AU - Malkus, Elizabeth C.

AU - Mendell, Jerry R.

AU - Flanigan, Kevin M.

AU - Miller, J. Philip

AU - Schierbecker, Jeanine R.

AU - Siener, Catherine A.

AU - Golumbek, Paul T.

AU - Zaidman, Craig M.

AU - McDonald, Craig M

AU - Johnson, Linda

AU - Nicorici, Alina

AU - Karachunski, Peter I.

AU - Day, John W.

AU - Kelecic, Jason M.

AU - Lowes, Linda P.

AU - Alfano, Lindsay N.

AU - Darras, Basil T.

AU - Kang, Peter B.

AU - Quigley, Janet

AU - Pasternak, Amy E.

AU - Florence, Julaine M.

AU - Anand, Pallavi

AU - Wulf, Charlie O.

AU - Goude, Erica

AU - Dalton, Joline C.

AU - Viollet-Callendret, Laurence

AU - Buser, Karen K.

AU - Shriber, Elizabeth

AU - Parad, Rebecca

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Introduction: Therapeutic trials in Duchenne muscular dystrophy (DMD) often exclude non-ambulatory individuals. Here we establish optimal and reliable assessments in a multicenter trial. Methods: Non-ambulatory boys/men with DMD (N=91; 16.7±4.5 years of age) were assessed by trained clinical evaluators. Feasibility (percentage completing task) and reliability [intraclass correlation coefficients (ICCs) between morning and afternoon tests] were measured. Results: Forced vital capacity (FVC), assessed in all subjects, showed a mean of 47.8±22% predicted (ICC 0.98). Brooke Upper Extremity Functional Rating (Brooke) and Egen Klassifikation (EK) scales in 100% of subjects showed ICCs ranging from 0.93 to 0.99. Manual muscle testing, range of motion, 9-hole peg test, and Jebsen-Taylor Hand Function Test (JHFT) demonstrated varied feasibility (99% to 70%), with ICCs ranging from 0.99 to 0.64. We found beneficial effects of different forms of corticosteroids for the Brooke scale, percent predicted FVC, and hand and finger strength. Conclusions: Reliable assessment of non-ambulatory boys/men with DMD is possible. Clinical trials will have to consider corticosteroid use.

AB - Introduction: Therapeutic trials in Duchenne muscular dystrophy (DMD) often exclude non-ambulatory individuals. Here we establish optimal and reliable assessments in a multicenter trial. Methods: Non-ambulatory boys/men with DMD (N=91; 16.7±4.5 years of age) were assessed by trained clinical evaluators. Feasibility (percentage completing task) and reliability [intraclass correlation coefficients (ICCs) between morning and afternoon tests] were measured. Results: Forced vital capacity (FVC), assessed in all subjects, showed a mean of 47.8±22% predicted (ICC 0.98). Brooke Upper Extremity Functional Rating (Brooke) and Egen Klassifikation (EK) scales in 100% of subjects showed ICCs ranging from 0.93 to 0.99. Manual muscle testing, range of motion, 9-hole peg test, and Jebsen-Taylor Hand Function Test (JHFT) demonstrated varied feasibility (99% to 70%), with ICCs ranging from 0.99 to 0.64. We found beneficial effects of different forms of corticosteroids for the Brooke scale, percent predicted FVC, and hand and finger strength. Conclusions: Reliable assessment of non-ambulatory boys/men with DMD is possible. Clinical trials will have to consider corticosteroid use.

KW - Corticosteroids

KW - Duchenne muscular dystrophy

KW - Non-ambulatory

KW - Pulmonary function

KW - Quality of life

KW - Strength

UR - http://www.scopus.com/inward/record.url?scp=84925350947&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925350947&partnerID=8YFLogxK

U2 - 10.1002/mus.24346

DO - 10.1002/mus.24346

M3 - Article

C2 - 25056178

AN - SCOPUS:84925350947

VL - 51

SP - 522

EP - 532

JO - Muscle and Nerve

JF - Muscle and Nerve

SN - 0148-639X

IS - 4

ER -